

# Index

Page numbers in bold refer to tables. Page numbers in *italics* refer to figures. Page numbers suffixed with 'b' refer to boxes.

- acarbose 297, 299b, 304  
acetoexamide **298**  
acetylation of DNA 17  
acetyl CoA carboxylase 252, 254  
acid labile subunit 74  
acidosis  
  diabetic ketoacidosis 279, **280**  
  parathyroid hormone 196  
acromegaly 75, 77–80, **81**, 97, 201  
ACTH *see* adrenocorticotrophic hormone  
Addison disease 13, 108–11, 124, 177, 231, 283  
Addisonian crisis 111  
adenosine-3',5'-cyclic monophosphate 37, 38  
adenylate cyclase 35, 37  
adjustment disorder, diabetes in children 335  
adrenal cortex **10**, 100–19  
  ACTH on 87  
  insufficiency 88, 108–11, 231  
  pigmentation 88, 124  
  tumours 116–18  
adrenalectomy 114  
  Conn syndrome 116  
adrenal gland, incidentaloma 60–1, 117, 125–6  
adrenaline (epinephrine) **53**, 119–22  
adrenal medulla **10**, 119–23  
adrenal vein sampling 116, 125  
adrenarche 102b, 138  
adrenocorticotrophic hormone (ACTH) **53**, 86–8, 102–5  
  on aldosterone synthesis 107  
  Cushing syndrome 113–14  
  stimulation test 231  
  synthetic ACTH test 88, 110, 124  
adrenoreceptors 120  
adult respiratory distress syndrome, diabetic ketoacidosis 282  
advanced glycation end-products (AGEs) 314–15  
  cardiovascular disease 331  
  receptors 315  
age  
  GH and IGF-I secretion 75–6  
  male sexuality 138  
  osteoporosis 206  
AGEs *see* advanced glycation end-products  
Agouti-related protein 347  
*AIRE* gene 212  
Albright hereditary osteodystrophy 40b, 199  
albumin  
  calcium and 191, 211–12  
  *see also* microalbuminuria  
aldose reductase inhibitors 315  
aldosterone 101, 106–7, *108*  
  excess (Conn syndrome) 115–16, 125  
  insufficiency, congenital adrenal hyperplasia 117–18  
  reference ranges **53**  
alendronate 207  
alkalosis, respiratory 211  
allergy, insulin 270  
alopecia *see* male-pattern balding  
 $\alpha$ -cells 219, 244, 248  
 $\alpha$ -melanocyte stimulating hormone 347  
 $\alpha$  subunits *see* G $\alpha$  protein subunits  
Amadori reaction 246  
amenorrhoea 83, 151–7, 164  
American Diabetes Association, classification of diabetes 238–40  
amino acids  
  derivatives 8–9, 20–4  
  growth hormone test **78**  
amiodarone 182, 184b, 189  
AMP kinase 300  
amputations, diabetes 325  
amylin analogues 308  
anabolic actions  
  growth hormone 74–6  
  insulin 250, 251  
  insulin-like growth factor I 75  
anabolic drugs  
  osteoporosis 207–8  
anaemia  
  hypothyroidism 187  
  metformin 300–1  
analgesics, diabetic neuropathy 324–5  
anaplastic carcinoma of thyroid 186  
androgens 134–6  
  adrenal *see* sex steroid precursors  
  deficiency 132  
  hirsutism 157  
  polycystic ovarian syndrome 154  
androstenedione **53**  
aneuploidy 56  
angina, diabetes 333  
angiotensins 107, *108*  
  *see also* renin–angiotensin–aldosterone axis  
antacids, hypercalcaemia 200

- antenatal care, diabetes 337
- antibiotics, diabetic foot 328
- antidepressants, diabetic neuropathy 324
- antidiabetes agents *see* oral antidiabetes agents
- antidiuretic hormone *see* vasopressin
- anti-inflammatory agents, glucocorticoids as 106
- anti-Müllerian hormone 53, 130
- antipsychotics, obesity 358–9
- antiresorptive drugs, osteoporosis 207
- antithyroid drugs 171b, 180, 188, 189
- fetus 181
- aorta, Turner syndrome 154
- apparent mineralocorticoid excess 41
- appetite control 347–50
- arachidonic acid 43
- arginine vasopressin *see* vasopressin
- aromatase inhibitors 229
- array comparative genomic hybridization 57
- arteries to thyroid 168
- aspirin 333
- atheroma, diabetes 331–2
- ATP-sensitive K<sup>+</sup> channel 218
- atrial natriuretic peptide 38
- autocrine cells 4
- autoimmune diseases 124, 175b, 231
- type 1 diabetes 258, 259–60
- autoimmune polyendocrine syndrome type 1 198, 211
- autoimmune thyroiditis 175
- see also* Graves disease
- autonomic neuropathy, diabetes 325, 326
- autonomic symptoms, hypoglycaemia 276
- baldness, male-pattern 157, 163–4
- bariatric surgery 357–8, 359
- diabetes prevention 293
- Beckwith–Wiedemann syndrome 20b
- β-blockers, hyperthyroidism 181, 188
- β-cells 244, 248
- type 2 diabetes 290–2
- bicarbonate, diabetic ketoacidosis 280, 281, 282
- big IGF-II 217
- biguanides 297, 300–1
- binding proteins 24
- biphasic release of insulin 244, 249, 290, 291
- birth weight, diabetes 288
- bisphosphonates 202, 207
- blindness, diabetic retinopathy 321
- blood pressure
- aldosterone on 107
- control, diabetes 322, 333
- cortisol action 106
- blood specimens 49
- hypercalcaemia 202
- hypoglycaemia 217
- blood supply
- islets of Langerhans 248
- thyroid 168
- body mass index 344
- diabetes 288, 289
- limitations 345–6
- bone 202–10
- cortisol action 106
- diabetic foot 328, 329
- growth hormone excess 77–8
- insulin-like growth factor I 75
- parathyroid hormone on 196–7
- bone mineral density 205–6, 207
- bread, calcium 192
- breast
- cancer 229–30
- prolactin and 86
- oxytocin on 96
- pregnancy 151
- thelarche 151
- breast-feeding, diabetes 338
- bromocriptine 86, 308
- bruit, Graves disease 188
- cabergoline 86
- calcification, ectopic 201
- calcitonin 195, 197, 207
- calcitriol *see* 1, 25-dihydroxyvitamin D
- calcium 191–203
- albumin and 191, 211–12
- exocytosis and 20
- negative feedback on vitamin D 193, 195
- parathyroid hormone and 196
- screening 226
- in second messenger pathways 37–8, 42
- calcium-sensing receptor (CaSR) 196
- activation 203
- inactivation 200
- calibration of immunoassays 49
- cAMP (cyclic adenosine monophosphate) 37, 38
- cAMP response element binding protein (CREB) 37
- cancer *see* malignant disease; neoplasia syndromes; *specific organs and tissues*
- candidiasis, autoimmune polyendocrine syndrome type 1 211
- cannabinoid-1 receptors 349
- capillary blood glucose monitoring 272–3
- carbimazole 188, 189
- fetus 181
- carbohydrates
- counting 271–2
- digestion 304
- carbon dioxide tension, vasopressin action 92
- carcinoid syndrome 221–3
- carcinoid tumours 221–2, 232
- cardiac failure, acromegaly 78
- cardiomyocytes, K<sup>+</sup> channels 299
- cardiovascular complications
- diabetes 313, 330–4, 341–2
- glucose levels 243
- glycated haemoglobin *vs* 245
- mortality 264
- nephropathy 321
- sulphonylureas 299

- Carney complex 227  
 carpal tunnel syndrome 324  
 cascades of enzymes 20–2  
 CaSR *see* calcium-sensing receptor  
 casts (plaster) 327  
 catabolism 106  
 catecholamines 119–22, 126  
   sample collection 49b  
   thyroid hormones and 173  
 catheterization (urinary), diabetic  
   ketoacidosis 281  
 cavernous sinus, cranial nerves **71**  
 CBG (cortisol-binding globulin)  
   101–2, 112  
 C-cells 167  
   hyperplasia 226  
 cell-surface receptors 28–31  
 cellulitis, Charcot arthropathy and  
   329  
 central obesity 346  
 cerebral oedema, diabetic  
   ketoacidosis 282  
 Charcot arthropathy 328–9  
 chemicals, diabetes triggers 262b  
 chemotherapy, testicular tumours  
   141  
 children, diabetes 258–9  
   adjustment disorder 335  
   ketoacidosis 280  
 chlorpropamide **298**  
   hyponatraemia 299  
 cholecalciferol (vitamin D<sub>3</sub>) 192–3,  
   210  
 cholecystokinin **216**, 221  
 cholesterol  
   hormones from 23, 103  
   reduction of levels 333  
   synthesis 24, 252  
   vitamin D synthesis from 192–3,  
     194  
 chromaffin cells 119, 120  
 chromogranin(s) 119  
 chromogranin A **53**  
 chromosomes 15, 16  
   abnormalities 20b  
   G-banding 56  
   karyotypes 56  
   sex determination 128–30  
 cinacalcet 203  
 circadian rhythm 13b, 73, 104, 110  
   *see also* diurnal variation  
 clozapine 358  
 codons 18  
 co-enzyme A 23  
 cognitive impairment  
   diabetes 335  
   hypoglycaemia 276  
 collagen 204b  
 colloid, thyroid 168, 171  
 colorectal carcinoma, growth  
   hormone excess 80  
 competitive-binding assays 51  
 complete gonadal dysgenesis 130,  
   131, 132  
 computed tomography 59–60  
 congenital adrenal hyperplasia 13,  
   117–18, 119, 126, 133,  
   162–3  
 congenital hyperinsulinism 218  
 congenital malformations  
   maternal diabetes 336–7  
   *see also* teratogenesis  
 Conn syndrome 115–16, 125  
 continuous subcutaneous insulin  
   infusion 269, 270  
 contrast media (radiographic),  
   thyroid inhibition by 175  
 control mechanisms 9–13  
 co-repressors, thyroid hormone  
   receptors and 41  
 coronary arteries, surgery 333–4  
 corpus luteum 143–4  
 corticotrophin-releasing hormone  
   87, 102–5  
 cortisol **53**, 101–6  
   excess (Cushing syndrome) 88,  
     111–15, 124–5  
   fetus 106, 150–1  
   growth hormone release 77  
   target cell conversion 41  
 cortisol-binding globulin (CBG)  
   101–2, 112  
 cortisone 105  
 Cortrosyn 110  
 C-peptide 214–17, 244, 247  
   hypoglycaemia 217  
 cranial diabetes insipidus 94, **95**  
 cranial nerves, cavernous sinus **71**  
 craniopharyngioma 70, 140  
 cravings for food 355  
 creatinine, estimated GFR 322b  
 CREB (cAMP response element  
   binding protein) 37  
 cretinism 170b  
 crystalloids 281  
 Cushing disease 88, 114  
 Cushing syndrome 88, 111–15,  
   124–5  
 cycles *see* rhythms  
 cyclic adenosine monophosphate  
   (cAMP) 37, 38  
 cyclo-oxygenases 43  
 CYP21A2, congenital adrenal  
   hyperplasia 117, 118  
 cyproterone acetate 229  
 cytochrome P450 enzymes 23–4  
   congenital adrenal hyperplasia  
     117  
   steroidogenesis 103, **104**  
   *see also* 1 $\alpha$ -hydroxylase  
 cytokine receptors 34  
 cytosolic guanylate cyclase 38  
  
 DAX1 gene 15, 42  
 DCCT-aligned HbA<sub>1c</sub> 273  
 dehydration, diabetes 263  
   ketoacidosis 278, 281  
 dehydroepiandrosterone (DHEA)  
   101, 107  
   fetus 150, 151  
   polycystic ovarian syndrome  
     154  
 $\delta$ -cells 219, 244, 248  
 depression, diabetes 334–5  
 De Quervain's subacute thyroiditis  
   176  
 desmopressin 94, **95**  
 DEXA (dual energy X-ray  
   absorptiometry) 201–2,  
   205–6, 207  
 dexamethasone 151  
   suppression tests 113, 114, 232  
 DHEA *see* dehydroepiandrosterone  
 diabetes insipidus 93–4, **95**, 97–8

- diabetes mellitus
- aetiology
    - type 1 260–3
    - type 2 287
  - bariatric surgery 357, 359
  - care strategy 335–6
    - pregnancy 337–8
  - classification 236, 238–41, **265**
  - complications 311–42
    - cancer 334
    - epidemiology 313
    - psychological 334–5
    - see also* cardiovascular
      - complications; ketoacidosis; microvascular complications
  - diagnosis 241–3, 244, 256, 264, **265**
  - environmental factors 262–3, 288–9
  - epidemiology 236–7, **238, 239**, 255
    - type 1 258–9
    - type 2 286–7
  - historical aspects 5, 238, 239–40b
  - ketoacidosis 263, 277–82, 284
    - pregnancy 337
  - management
    - type 1 264–74
    - type 2 296–308
  - neonates 218, 246
  - obesity 288, 289, 309, 344–5
  - orlistat 356
  - pathogenesis
    - type 1 259–60
    - type 2 289–92
  - pregnancy 150, 336–9
    - gestational diabetes 309, 338, **339**
    - screening for retinopathy 318–20
  - prevention 293–4, 295b
  - prognosis
    - type 1 263–4
    - type 2 292
  - screening *see under* screening
  - social aspects 339–40
  - type 1 257–84
    - type 2 285–310
    - undiagnosed 292, 293
    - see also* maturity-onset diabetes of the young
- diacylglycerol 37–40, 42
- DIDMOAD syndrome **95**
- diet
- calcium intake 192
  - diabetes 271–2, 293–4, 295b, 296
  - for obesity 354–6
  - trends 350–1
  - vitamin D 192
    - on zona glomerulosa 107
- DiGeorge syndrome 56, 198
- 5 $\alpha$ -dihydrotestosterone 130
- 1,25-dihydroxyvitamin D (calcitriol) 193, 194
- for hypocalcaemia 199
- 24,25-dihydroxyvitamin D 193
- dipeptidyl peptidase 4 (DPP-4), inhibitors 221, 297, 299b, 304, **307**
- diplopia, pituitary tumours and 69
- distal symmetrical neuropathy 324
- diurnal variation
  - insulin secretion 266
  - loss in Cushing syndrome 113
  - testosterone 136
  - see also* circadian rhythm
- DNA 15, 17, 20b
- DNA repair genes 224b
- dopamine agonists 80
  - for prolactinomas 85
- dopamine receptor antagonists, on prolactin 85
- DPP-4 *see* dipeptidyl peptidase 4
- drinks, obesity and 351
- driving, diabetes 339–40
- dual energy X-ray absorptiometry (DEXA) 201–2, 205–6, 207
- duloxetine, diabetic neuropathy 324
- duodenum, hormones **11**
- duplication of chromosomes 15
- dynamic testing 52, 56b
  - hypoadrenalism 110
- eating behaviour 349, 350–1, 352, 355, 358
- ectopic ACTH secretion 114, 232
- ectopic calcification 201
- ectopic hormone syndromes 227–8
- education, diabetes 270–1
- eflornithine 158
- eicosanoids 38–40, 43
- embryogenesis 143
- embryology
  - adrenal cortex 100, 101
  - adrenal medulla 119
  - parathyroid glands 196
  - pituitary 66–7
  - reproductive organs 128–34
  - thyroid 166–8
- embryonal carcinoma 141b
- emergencies
  - diabetes 274–82
  - hypercalcaemia 202
  - hyperosmolar hyperglycaemic state 293
- employment, diabetes and 340
- endocannabinoids 349
- Endocrine Postulates (Doisy) 9b
- endocrine system 4
- endometriosis 158
- endometrium
  - cancer 230
  - menstrual cycle 145–7
- endopeptidases 20
- energy balance 347
- enteroendocrine cells 220
- enzymes 20–2
  - assays 52
  - mineralocorticoid receptors and 106–7
  - steroidogenesis 103, **104**
- epidermal growth factor receptor blockers 229–30
- epigenetics 17, 20b
- epinephrine **53**, 119–22
- eplerenone 116
- $\epsilon$ -cells 244
- erectile dysfunction, diabetes 313, 329–30, 341
- ergocalciferol (vitamin D<sub>2</sub>) 192–3

- erythropoietin receptors (EPO receptors) 34
- estimated glomerular filtration rate 322b
- ethnicity
- diabetes 287
  - obesity 346
- exenatide 304–5
- exercise
- diabetes 272, 288, 293–4, 295b, 296–7
  - obesity and 351–2, 356
- exocytosis 20
- exophthalmos (proptosis) 181–2, 183
- extracellular domains, cell-surface receptors 29
- ezetimibe 333
- falls 207
- familial benign hypercalcaemia 200–1, 212
- familial endocrine neoplasia 223–7
- familial isolated hyperparathyroidism 226
- familial male precocious puberty 39
- familial pheochromocytoma syndromes 227
- familial risk of diabetes 262, 287–8
- fast-food outlets 350, 351
- fasting
- glucose levels
    - diabetes diagnosis 241, 244, 294
    - regulation 251
    - see also* impaired fasting glycaemia
  - growth hormone regulation 77
  - insulin secretion 244
  - sample collection and 49b
- fat (dietary) 351
- fatty acids
- insulin on metabolism 252, 253
  - non-esterified 278–9
  - Randle cycle 303b
  - release, catecholamines 120–1
  - see also* free fatty acids
- feedback *see* negative feedback; positive feedback
- feminization, adrenocortical 116
- femoral amyotrophy 324
- fertility
- management 153
  - polycystic ovarian syndrome 157
  - sub-fertility 159–62, 164
- fertilization 148
- fetus
- adrenal androgens 107
  - antithyroid drugs 181
  - cortisol 106, 150–1
  - hyperthyroidism 181
  - iodine deficiency 170b
  - maternal diabetes 336–7
  - steroid hormone synthesis 150, 151
- FFA *see* free fatty acids
- fibroids 158
- finasteride 229
- fine-needle aspiration cytology, thyroid nodules 185
- flozins 308
- fludrocortisone 110
- fluid retention, thiazolidinediones 302
- fluid therapy, diabetic ketoacidosis 280, 281
- fluorescence *in situ* hybridization 56–7
- follicles
- ovary 142–3
  - thyroid 167, 168
- follicle-stimulating hormone 89–90
- hypogonadism 139–40
  - menopause 149
  - molecule 8
  - on ovary 144, 145, 146
  - reference ranges 53
  - synthesis 21
  - testis regulation 136–7, 138
- follicular carcinoma of thyroid 186
- follicular phase of menstrual cycle 149
- food trends 350, 351, 355
- foot ulcers, diabetes 313, 325–9, 341
- fractures 212
- osteoporosis 206
- free fatty acids (FFA)
- cortisol on metabolism 105
  - growth hormone and 77
- fructosamine 273–4
- galactorrhoea 158, 163
- G $\alpha$  protein subunits 36, 38b, 39
- gas chromatography 52
- gastrin 53, 215, 220
- gastrinomas 219b, 220, 231
- gastrointestinal barriers 358
- gastrointestinal hormone-secreting tumours 219b
- gastrointestinal tract 220–3
- acarbose 304
  - appetite control 347–8
  - metformin on 300
- G-banding of chromosomes 56
- G-cells 220
- gender differences, obesity 345, 346
- genes 15
- diabetes 261, 288, 289
  - obesity 347, 349–50
  - sequencing 57
  - transcription 16–17
  - translation 18
  - tumours and 223–4, 225
- genome-wide microarray technology 57
- genomic imprinting 17
- genomics 57
- genotypes 57
- germ cells
- embryology 130
  - oogenesis 142
- germ cell tumours of testis 141
- germline mutations, catecholamine-secreting tumours 122–3
- gestational age 147
- gestational diabetes 309, 338, 339
- ghrelin 77, 215, 220, 347–8
- gigantism 77–80
- glibenclamide 298
- gliclazide 298

- glimepiride **298**  
 glipizide **298**  
 gliquidone **298**  
 glitazones (thiazolidinediones) 297,  
 299b, 301–3, **307**  
 glomerular filtration rate, estimated  
 322b  
 glucagon **215**, 219, 254  
   for hypoglycaemia 276–7  
   reference ranges **53**  
 glucagon-like peptide 1 (GLP-1)  
   **216**, 221  
   receptor agonists 304–5, **307**,  
   357, 359  
 glucagonomas 219  
 glucocorticoids  
   growth hormone release 77  
   therapeutic uses 106, 118–19  
   *see also* cortisol  
 gluconeogenesis 252  
 glucose  
   cortisol on metabolism 105  
   diabetes  
     diagnosis 241–3, 244  
     effect of exercise 272b  
     ketoacidosis management 281  
     monitoring 272–3, 283  
     screening 294, **295**  
   digestion 303–4  
   GH and IGF-I on homeostasis  
     74  
   insulin on metabolism 250–2,  
     253  
   insulin stimulation 244–6  
   reference ranges **53–4**  
   release, catecholamines 120  
   renal threshold 263  
   tolerance test *see* oral glucose  
     tolerance test  
   *see also* hyperglycaemia  
 glucose-dependent insulinotropic  
   peptide **216**, 221  
 glucose transporters (GLUT) 31,  
   251–2  
 glucosidase inhibitors 297  
 glutathione, reduced 315  
 glycated haemoglobin (HbA<sub>1c</sub>) 315b  
   Amadori reaction 246  
 diabetes complications 245, 331,  
   332  
 diabetes control 273  
 diabetes diagnosis 243  
 diabetic retinopathy 321  
 limitations 274b  
 reference ranges **54**  
 screening 294–5  
 target levels 296  
 glycolysis 252  
 goitre 170, 175  
   Graves disease 176  
   multinodular 184–5,  
     189  
 goitrogens 170  
 gonadotrophin-releasing hormone  
   (GnRH) 89, 137  
   analogues 229  
   test 140, 153  
   treatment with 73  
 gonadotrophins 89–90, 136–7,  
   138  
   amenorrhoea 153  
   molecules 8  
   pulsatility 148  
   *see also* follicle-stimulating  
     hormone; luteinizing  
     hormone  
 gonads  
   complete dysgenesis 130, 131,  
     132  
   embryology 128–30  
 G-protein-coupled receptors 30,  
   34–40  
 G-proteins 35  
   subunits 35  
   *see also* G $\alpha$  protein subunits  
 Gq $\alpha$  subunit 37–8  
 Graafian follicles 143  
 granules (secretory) 20  
 Graves disease 178–82  
   goitre 176  
 Graves orbitopathy 181–2, 183,  
   188–9  
 growth  
   cortisol action 106  
   insufficiency 82  
 growth factor receptor-bound  
   protein type 2 (Grb2  
   protein) 31  
 growth hormone 73–83  
   deficiency 80–3  
   hypoglycaemia 217  
   excess (acromegaly) 75, 77–80,  
     **81**, 97, 201  
   immunoassay 49–50  
   reference ranges **54**  
   regulation 76–7  
   replacement therapy 82–3  
   resistance syndromes 37  
   signal transduction 34, 35, 76  
 growth hormone-IGF-1 axis 76  
   diabetic complications 316  
 growth hormone-releasing hormone  
   (GHRH) 76  
 guanylate cyclase, cytosolic 38  
 guar gum 303  
 guidelines, diabetes type 2  
   management 306  
 gynaecomastia 142  
  
 haemodynamic theory, diabetic  
   complications 316  
 half-life of growth hormone 76  
 Hashimoto thyroiditis 175  
 hCG *see* human chorionic  
   gonadotrophin  
 headache, pituitary tumours 70  
 heart  
   Turner syndrome **154**  
   cabergoline 86  
   carcinoid syndrome 223b  
   *see also* cardiovascular  
     complications  
 heart failure, acromegaly 78  
 heat-shock proteins, steroid  
   hormone receptors and  
   41  
 hemianopia 68, 96  
 hepatocyte nuclear family,  
   transcription factors 43  
 HER2 antagonists 229–30  
 hermaphroditism 130–4  
 heterozygosity 57  
 hexosamine pathway 316

- high-dose dexamethasone  
suppression test **113**, 114
- hirsutism 157–8  
polycystic ovarian syndrome  
**155**
- historical aspects 4–5, 6b, 7–8  
diabetes 5, 238, 239–40b  
insulin 267
- HLA haplotypes, diabetes 261
- HMGCoA reductase inhibitors 23,  
333
- home testing, Cushing syndrome  
113
- HONK *see* hyperosmolar  
hyperglycaemic state
- hormone(s) 5–6  
historical aspects 4–5
- hormone replacement therapy 153,  
158, 207
- hormone response elements  
steroid hormone receptors 41
- hormone-secreting tumours  
gastrointestinal 219b
- hormone-sensitive lipase 278
- hormone-sensitive tumours  
228–30
- human chorionic gonadotrophin  
(hCG) 141, 145, 149–50  
delayed puberty and 159  
molecule 8  
synthesis 21  
as tumour marker 230
- human leukocyte antigens (HLA)  
262b  
haplotypes, diabetes 261
- human menopausal gonadotrophins  
141
- hydrocortisone 110, 114, 124, 231
- hydroxyapatite 203
- 5-hydroxyindoleacetic acid 222
- 1 $\alpha$ -hydroxylase 193–5  
magnesium deficiency on 198
- 24-hydroxylase 193
- hydroxymethylglutaryl co-enzyme A  
23
- hydroxymethylglutaryl co-enzyme A  
reductase inhibitors 23, 333
- 17-hydroxyprogesterone **53**
- 11 $\beta$ -hydroxysteroid dehydrogenase  
105  
type 2 41
- 25-hydroxyvitamin D 193
- hygiene hypothesis 263
- hyperadrenalism 111–19
- hypercalcaemia 200–3, 211–12
- hyperemesis gravidarum,  
hyperthyroidism  
178
- hyperglycaemia 278  
cardiovascular complications 331,  
332  
microvascular complications  
313b, 314–16  
neuropathy 324  
teratogenesis 336–7  
*see also* hyperosmolar  
hyperglycaemic state
- hyperinsulinism, congenital 218
- hyperkalaemia  
diabetic ketoacidosis 279  
neonates 118
- hyperosmolar hyperglycaemic state  
293
- hyperparathyroidism 200, 201–3,  
210  
familial isolated 226  
MEN-1 224  
screening 226
- hyperprolactinaemia 83–6, 97
- hypertension  
Conn syndrome 115  
diabetes 313b, 316, 341  
nephropathy 322  
phaeochromocytoma 122
- hyperthyroidism 178–85, 188  
thyroid function tests 174  
treated thyroid nodules 185
- hypertriglyceridaemia, diabetes  
331–2
- hyperventilation 211
- hypoadrenalism 108–11, 231  
secondary 111
- hypocalcaemia 198–9, 211
- hypoglycaemia 217–18, 231,  
274–7, 283–4  
antenatal care 337  
driving and 339–40  
sulphonylureas 217, 298
- hypogonadism  
female 153  
male 138–41, 163  
secondary 90
- hypogonadotrophic hypogonadism  
90
- hypokalaemia  
causes 116b  
Conn syndrome 115
- hyponatraemia 93, 108–9  
chlorpropamide 299
- hypoparathyroidism 198, 199, 211
- hypophosphataemic rickets 210
- hypophyseal portal vessels 68
- hypopituitarism 90–1
- hypoprolactinaemia 86
- hypospadias 132
- hypothalamic–anterior pituitary  
hormone axes 72–3  
adrenal cortex 102–5  
ovary 144, 147  
testis 136–7
- hypothalamus 66, 67, 68, 70–2  
amenorrhoea 153  
growth hormone regulation 76–7  
hormones **10**, 72  
nuclei **69**  
weight regulation 347
- hypothyroidism 175–8, 187–8  
cretinism 170b  
hypothalamic–anterior pituitary  
hormone axis 72–3  
iodide deficiency 170  
Pendred syndrome 171  
pituitary 174  
secondary 178  
thyroid function tests 174, 177–8
- hypovolaemia, diabetes 263
- IGF-I *see* insulin-like growth factor I
- IGF-binding proteins 74
- immunoassays 49–51
- impaired fasting glycaemia 241, 243
- impaired glucose tolerance 241, 243
- incidentalomas, adrenal 60–1, 117,  
125–6



- incretins 221  
   antidiabetes agents and 304–6  
 infections, diabetes 262b  
   foot 327–8, 341  
   ketoacidosis 277  
 inferior petrosal sinus sampling 114  
 infertility (sub-fertility) 159–62, 164  
 inflammation, cortisol action 106  
 infradian rhythm 13b  
 inhibin 137, 139–40  
 inhibition 11, 12  
 injections of insulin 268–70  
   after diabetic ketoacidosis 282  
 inositol triphosphate (IP<sub>3</sub>) 37–8  
 insulin 214–19, 243–54  
   action 246–54  
   analogues 267, 282  
   diabetes management 265–70, 283  
   type 2 diabetes 307, 309–10  
   diabetic ketoacidosis **280**  
   management 281–2  
   effects of GH and IGF-I 74  
   fetus 150  
   formulations 266–7  
   molecule 8, 11  
   reference ranges **54**  
   resistance  
     cortisol promoting 105, 106b  
     diabetes 289–90, 291b  
     polycystic ovarian syndrome **155**  
     pregnancy 337  
     syndromes 34b  
   responsiveness 290b  
   secretagogues 297  
   secretion 244–6, 247, 249, **249**  
     type 2 diabetes 290, 291, 292  
   sensitivity 290b  
   sensitizers 300–1  
   signal transduction 31–3, 34b, 248, 250, 291b  
   synthesis 21, 214–17, 244, 247  
   tolerance test **78**, 88  
 insulin-like 3 130  
 insulin-like growth factor I (IGF-I) 34, 35b, 74  
   anabolic actions 75  
   diabetic complications 316  
   gene defects 37b  
   reference ranges **54**  
   signal transduction 76  
 insulin-like growth factor-II, alternative 217  
 insulinomas 217–18, 219b  
 insulin promoter factor 1 43  
 insulin receptor 31, 248, 291b  
 insulin responsive substrates 248  
 insulin zinc suspensions 267  
 intermediate metabolism, insulin on 249–54  
 internal carotid artery, pituitary tumours enveloping 69  
 intersex 131–3  
 intrinsic TK receptors 31  
*in vitro* fertilization 164  
 iodide  
   deficiency 170  
   thyroid inhibition 175  
   uptake 168, 169  
 iodination of thyroglobulin 170  
 iodine-131 180–1  
 islets of Langerhans **10**, 214–20, 244, 248  
 IVF (*in vitro* fertilization) 164  
 Janus kinase family 34, 36  
 jejunum, hormones **11**  
 juxtaglomerular apparatus 107, 109  
 Kallman syndrome 90, 139  
 karyotypes 56  
 K-cells 221  
 ketoacidosis 263, 277–82, 284  
   pregnancy 337  
 ketone bodies 278–9  
   monitoring 281  
 kidney  
   aldosterone on 107  
   cortisol action 106  
   nephrons 109  
   proximity to adrenal 100  
   vasopressin action 92  
 Klinefelter syndrome 15, 133, 163  
 lactation 151  
   cortisol action 106  
   prolactin 83  
 lactic acidosis 301  
 Laron syndrome 37  
 laser photocoagulation, diabetic retinopathy 321  
 late-onset male hypogonadism 138  
 L-cells 221  
 leprechaunism 34b  
 leptin 348–9  
 Leydig cell tumours 141  
 life-expectancy, diabetes 264  
 lipids  
   cortisol on 105  
   diabetes 331–2, 341–2  
   growth hormone and FFA on 77  
   insulin on metabolism 252, **253**  
   pioglitazone on 302  
 lipoatrophy 270  
 lipohypertrophy 270  
 lipolysis, diabetic ketoacidosis 278  
 liquid chromatography 52  
 liraglutide 305, 357  
 lithium 175  
 liver  
   hormone **11**  
   insulin on 250  
   thiazolidinediones 302–3  
 loss of heterozygosity 57  
 low-dose dexamethasone suppression test 113  
 low-fat diets 355  
 lung  
   cancer 232  
   cortisol on development 106, 150–1  
 luteal phase of menstrual cycle 145, **149**  
 luteinizing hormone 89–90  
   hypogonadism 139, 140  
   menopause 146  
   molecule 8  
   on ovary 144, 145, 147  
   reference ranges **54**  
   synthesis 21  
   on testis 136–7, 138



- macroadenomas, pituitary 67  
 macrocytosis 124  
 macroprolactin 84  
 macrosomia 336  
 macrovascular complications *see*  
     cardiovascular complications  
 magnesium deficiency 198  
 magnetic resonance imaging 59–60  
 malabsorption, orlistat 356  
 male-pattern balding 157, 163–4  
 malignant disease  
     diabetes 334  
     hypercalcaemia 200, 201b  
     *see also* neoplasia syndromes;  
         *specific organs and tissues*  
 malnutrition-related diabetes 240  
 MAPK pathway 33, 36  
 mass spectrometry 51–2  
 maternal diabetes 288, 336–7  
 maternal history, diabetes 288  
 maturity-onset diabetes of the young  
     256  
     mutations 43, 240, **241**, 246  
     type 1 diabetes *vs* 264  
 McCune–Albright syndrome 40,  
     227  
 medullary thyroid carcinoma 57,  
     186, 226  
     familial 227  
 meglitinides 297, 300  
 meiosis 15, 16, 17  
 melanocortin receptors 87, 347  
 melatonin 73  
 MEN-1 (multiple endocrine  
     neoplasia) 224–6  
 MEN-2 (multiple endocrine  
     neoplasia) **225**, 226, 232  
 menopause 146  
     gonadotrophins 89  
     hormone replacement therapy  
         158  
     osteoporosis 206  
 menstrual cycle 142, 144–5, **149**  
     sub-fertility 161  
 mesonephric ducts 130  
 metabolic acidosis  
     diabetic ketoacidosis 279, **280**  
     parathyroid hormone 196  
     metabolic syndrome 332, 333b  
 metabolism, effects of GH and  
     IGF-I 74–6  
 metacarpals,  
     pseudohypoparathyroidism  
         198  
 meta-iodobenzylguanidine,  
     radiolabelled 61  
 metanephrine  
     reference ranges **54**  
     screening 226  
 metastases  
     adrenal cortex 116  
     carcinoid tumours 232  
     endometrial cancer 230  
 metformin 299b, 300–1, 306  
     cardiovascular complications and  
         331  
     insulin with 307  
 methylation of DNA 17, 20b  
 microadenomas, pituitary 67  
 microalbuminuria 321–2  
 microarray technology 57  
 microheterogeneity 52  
 microvascular complications of  
     diabetes 312–30  
     clinical features 317–30  
     glucose levels and 243  
     glycated haemoglobin *vs* 245  
     pathogenesis 312–17  
 midwifery, diabetes 338  
 milk, goitrogens 170  
 mineralocorticoid receptors 106–7  
     cortisol inactivation 41  
 mineralocorticoids  
     Conn syndrome 115–16, 125  
     *see also* aldosterone  
 mitogen-activated protein kinase  
     pathway 33, 36  
 mitosis 15, 16  
 mitotane 117  
 mixed insulin 268  
 monofilaments, sensory testing 327  
 monogenic disorders 259  
     obesity 349–50  
     renal tubules 116b  
 mononeuropathies, diabetes 324  
 morning sample collection 49b  
 mortality  
     body mass index 344  
     diabetes 237, 263–4  
 mosaicism 56  
 motilin **216**, 221  
 mRNA 17, 18  
     insulin on 252  
 Müllerian ducts 130  
 multinodular goitre 184–5, 189  
 multiple endocrine neoplasia  
     syndromes 122–3, 200,  
         224–7, 232  
 muscle, cortisol action 105–6  
 mutations 18, 20b  
     catecholamine-secreting tumours  
         122–3  
     diabetes 240, **241**  
     diagnosis 57  
     *see also specific genes*  
 myocardial infarction, diabetes  
     330–1, 333, 342  
 myxoedema coma 177b  
  
 nateglinide 300  
 National Institute of Health  
     and Clinical Excellence,  
     diabetes type 2 management  
         306  
 necrolytic migratory erythema 219  
 needles, insulin injection 268–9  
 negative feedback 11, 12, 72–3, 74  
     calcium on vitamin D 193, 195  
     parathyroid hormone 196  
     testosterone 137  
 negative pressure wound therapy  
     329b  
 Nelson syndrome 88  
 neonate  
     congenital adrenal hyperplasia  
         118, 119  
     diabetes 218, 246  
     hypocalcaemia 198  
     hypoglycaemia 218  
     sexual development 138  
 neoplasia syndromes 223b  
     carcinoid syndrome 221–3  
     familial endocrine neoplasia  
         223–7

- multiple endocrine neoplasia
  - syndromes 122–3, 200, 224–7, 232
- nephrogenic diabetes insipidus 94, **95**
- nephrologists, referral for diabetic nephropathy 322
- nephrons 109
- nephropathy, diabetic 313, 321–3
- neural crest 119
- neuroendocrine cells 4
- neurofibromatosis type 1 227
- neurogenin-3 214
- neuroglycopenic symptoms 276
- neurohypophysis *see* pituitary, posterior
- neuropathy, diabetes 323–5
  - foot ulcers 326, 327
- neuropeptide Y 347
- neutrophils, glucocorticoids and 106
- nicotinamide adenine dinucleotide phosphate 252
- nitrates, phosphodiesterase type 5 inhibitors and 330
- Nobel prize winners 7–8
- nodules, thyroid 184–5
- non-esterified fatty acids 278–9
- non-functioning adenomas, pituitary 67–70, 88, 90
- norepinephrine 119–22
  - reference ranges **54**
- normetanephrine
  - reference ranges **54**
  - screening 226
- nuclear medicine 60–1
  - hyperthyroidism 180
- nuclear receptors 40–2, 44, 45, 46
  - thiazolidinediones on 301, 302
- nucleosides 15b
- nucleotides 15b
- obesity 343–59
  - cortisol promoting 105
  - diabetes 288, 289, 309, 344–5
  - environmental factors 350–2
  - prohormone convertase 1/3 deficiency 87
  - trends 346–7
- obstructive sleep apnoea 309
- octreotide 221
- oedema, growth hormone 76
- oestradiol 144, 145
  - reference ranges **54–5**
  - from testosterone 136
- oestrogen receptors, breast cancer 229
- oestrogens 144–146, 146, **149**
  - feto-placental unit 150, 151
  - on growth hormone release 77
  - menopause 146
  - replacement therapy 153
- oncogenes 225
  - see also* proto-oncogenes
- oogenesis 142
- ophthalmologists, referral for diabetic retinopathy 320
- ophthalmopathy (Graves) 181–2, 183, 188–9
- ophthalmoplegia 68
- opiates, diabetic neuropathy 324–5
- optic chiasm compression 67, 70, 71
- oral antidiabetes agents 297–308
- pregnancy 338
- oral glucose tolerance test (OGTT) 241, 242, 243b
  - growth hormone status 77, **78**
- orlistat 356–7
- orphan nuclear receptors 40, 41–2
- osmolality, vasopressin action 92
- osmotic effects, diabetes 263, 340–1
- osteoblasts 204
  - parathyroid hormone on 196–7
- osteoclasts 204
- osteodystrophy, renal 200
- osteoid 203
- osteomalacia 208, 210
- osteomyelitis, diabetic foot 328
- osteopaenia 207
- osteoporosis 205–8, 212
- ovarian reserve 146
- ovary 142–6
  - cancer 230
  - embryology 128–30
  - hirsutism 157
  - hormones **11**
  - premature failure 153
  - see also* polycystic ovarian syndrome
- ovulation 142–3, 144–5
  - induction 162
- oxygen tension, vasopressin action 92
- oxytocin 94–6
  - molecule 8
- pain,
  - diabetic neuropathy 324–5
  - retro-orbital 188–9
- pancreas **10**, 214–20
- pancreas duodenal homeobox factor 1 43
- pancreatic polypeptide **215**, 220
  - reference ranges **55**
- pancreatitis, exenatide 305
- papillary cell cancer of thyroid 185–6
- paracrine cells 4
- paraesthesia 211
- paragangliomas 121, 122, **123**, 227
- parathyroid glands 166, 196
  - insufficiency 198, 199, 210
  - selective excision 202
  - venous sampling 202
  - see also* hyperparathyroidism
- parathyroid hormone **195**, 196–7
  - hypercalcaemia 202
  - reference ranges **55**
  - resistance syndromes 198–9
  - venous sampling 202
  - see also* teriparatide
- parathyroid hormone-related peptide 197
- parturition 151
  - diabetes 338
- pathognomonic (term) 265b
- PCSK1 (prohormone convertase 1/3) 87, 221, 244

- pegvisomant 35, 80  
 pelvic inflammatory disease 164  
 pen devices, insulin 268–9, 270  
 Pendred syndrome 171  
 peptide hormones 8  
   sample collection 49b  
   storage and secretion 20  
   synthesis 19–20  
 perchlorate 168  
 performance-enhancing drugs,  
   hypogonadism 139  
 perinatal factors, diabetes 262b  
 periodicity *see* rhythms  
 peripheral neuropathy 324  
 peripheral vascular disease, diabetic  
   foot 326  
 pernicious anaemia 175b  
 peroxisome proliferator-activated  
   receptor gamma 301, 302  
 pertechnetate, technetium isotope  
   168  
 phaeochromocytoma 121–3, 126,  
   232  
   familial syndromes 227  
   MEN-2, screening 226  
   nuclear medicine 61  
 phenotypes 57  
 phenoxybenzamine 122  
 phenylethanolamine *N*-methyl  
   transferase 119  
*PHEX* gene 192  
 phosphate 192  
   parathyroid hormone on 197  
   on vitamin D synthesis 195  
 phosphatidylinositol (PI) 35, 38, 42  
 phosphatidylinositol-3-kinase 31  
 phosphodiesterases 37  
 phosphodiesterase type 5 inhibitors  
   330  
 phospholipase C 35, 42  
 phosphorylation of proteins, signal  
   transduction 30, 31–3  
 physical activity *see* exercise  
 phytic acid 192  
 PI3 kinase pathway 33, 36  
 pigmentation, adrenocortical  
   insufficiency 88, 124  
 pioglitazone 301  
*PIT1* mutations 43  
 pituitary 66–7, 68  
   ablation for retinopathy 317  
   anterior 66–7  
     amenorrhoea 153  
     cell types 73  
     hormones 10, 73–91  
     *see also* hypothalamic–anterior  
       pituitary hormone axes  
   hypothyroidism 174  
   infarction 91  
   insufficiency 90–1  
   magnetic resonance imaging 60  
   posterior 66–7  
     hormones 10, 91–6  
   tumours 67–70, 96–7  
     acromegaly 78  
     Cushing disease 88  
     hyperprolactinaemia 85  
     non-functioning adenomas  
       67–70, 88, 90  
     radiotherapy 70, 71  
     TSHomas 89  
     visual field defects 67–8, 71,  
       96  
     *see also* Cushing disease  
 pituitary-specific transcription factor  
   1 43  
 placenta, steroid hormone synthesis  
   150, 151  
 placental lactogen 151  
 poly-A tail 17  
 polycystic ovarian syndrome  
   (PCOS) 154–7, 163  
   sub-fertility 161–2  
 polycythaemia, testosterone  
   replacement therapy 140–1  
 polydipsia 94, 95, 98  
 polymerase chain reaction 57, 58  
 polyol pathway 314, 315  
 POMC *see* pro-opiomelanocortin  
 portal vein (hepatic), insulin 250  
 portal vessels (hypophyseal) 68  
 portion sizes, food 351, 355  
 positive feedback 12, 74  
   oxytocin 96  
   prolactin 83  
 postnatal care, diabetes 338  
 post-prandial regulators  
   (meglitinides) 297–8, 300  
 post-translational modification of  
   peptides 19–20, 21  
 potassium, diabetic ketoacidosis  
   279, 280, 281  
 potassium channels  
   ATP-sensitive 218  
   cardiomyocytes 299  
   inward rectifying channel type 6.2  
   246, 298  
 PPAR- $\gamma$  (peroxisome proliferator-  
   activated receptor gamma)  
   301  
 pramlintide 308  
 pre-conception care, diabetes 337  
 pregabalin 324  
 pregnancy 147–51  
   diabetes 150, 336–9  
     gestational diabetes 309, 338,  
     **339**  
     screening for retinopathy  
     318–20  
 Graves disease 178, 181  
 prolactin 83  
 prolactinomas 86  
 sex hormones **149**  
 thyroid-stimulating hormone  
   174  
 premature ovarian failure 153  
 pre-prohormones 19  
 pressure palsies, diabetic neuropathy  
   324  
 pretibial myxoedema 183, 188  
 progestagens, endometrial cancer  
   230  
 progesterone **149**  
   endometrial cancer prevention  
   230  
   measurement 145  
   menopause 158  
   polycystic ovarian syndrome 157  
   reference ranges **55**  
   synthesis 144  
 progestins 229  
 prohormone convertase 1/3 (PC1/3)  
   87, 221, 244  
 prohormones 8, 19–20, 21

- proinsulin 247  
 prolactin 83–6, 137, 151  
   reference ranges 55  
   signal transduction 34  
 prolactinomas 84, 85, 163  
 pregnancy 86  
 promoters, gene transcription 16  
 pro-opiomelanocortin 86, 87  
   mutations and appetite 347  
 propranolol, hyperthyroidism 181, 188  
 proptosis 181–2, 183  
 propylthiouracil, fetus 181  
 prostaglandin(s) 43  
 prostaglandin E 330  
 prostate  
   cancer 228–9  
   testosterone replacement therapy 141  
 protamine insulin 267  
 protein(s)  
   insulin on metabolism 252–3  
   phosphorylation, signal transduction 30, 31–3  
 protein binding 24  
   androgens 136  
   calcium 191  
   cAMP response element binding protein 37  
   competitive-binding assays 51  
   cortisol-binding globulin 101–2, 112  
   IGF-binding proteins 74  
   thyroid hormones 172  
   *see also* sex hormone-binding globulin  
 protein kinase A 37  
 protein kinase C (PKC) 38–40  
 protein kinase C  $\beta$  314, 316  
 proton pump inhibitors 220  
 proto-oncogenes 223–4  
   *RET* 57, 226, 232  
 provocative tests 52  
 pseudo-Cushing syndrome 113  
 pseudohypoparathyroidism 198–9  
 psychogenic polydipsia 94, 95, 98  
 psychological complications of diabetes 334–5  
 psychological factors, obesity 352–3  
   eating behaviour 355  
 puberty  
   delayed 90, 159, 164  
   failure 133  
   female 146  
   male 138  
   precocious 159, 160  
     central 89–90  
     familial male 39  
     sex steroid precursor action *vs* 107  
 pubic hair, female 146  
 pulsatility  
   gonadotrophins, female 146  
   growth hormone release 76  
   hypothalamic hormone release 73  
 pumps (insulin infusion) 269, 270  
 pyramidal lobe of thyroid 167  
  
 quality of life, diabetes 334  
  
 radiculopathies, diabetes 324  
 radiocontrast dyes, thyroid inhibition by 175  
 radioiodine 180–1  
 radionuclide imaging *see* nuclear medicine  
 radiotherapy  
   acromegaly 80, 81  
   hypopituitarism from 91  
   pituitary tumours 70, 71  
 Randle cycle 303b  
 Rathke's pouch 66–7  
 receptors 27–47  
   *see also* nuclear receptors  
 recombinant insulin 267  
 recombination, chromosomes 16  
 5 $\alpha$ -reductase (SRD5A2) 135–6  
   inhibitors 157–8, 229  
 reduced glutathione 315  
 reference ranges 52, 53–5  
 regulation (control mechanisms) 9–13  
 remodelling of bone 204–5  
 renal artery stenosis 341  
 renal failure  
   hyperparathyroidism 200  
   hypocalcaemia 198  
 renal replacement therapy 323  
 renal threshold, glucose 263  
 renal tubules, monogenic defects 116b  
 renal units, referral for diabetic nephropathy 322  
 renin 107, 110  
   Conn syndrome 116  
   reference ranges 55  
 renin–angiotensin–aldosterone axis 108  
   Conn syndrome 115  
   diabetic complications 316  
 repaglinide 300  
 reproductive endocrinology 127–64  
   female 142–58  
   male 134–42  
 resistance syndromes  
   G-protein–coupled receptors 40b  
   growth hormone 37  
   insulin 34b  
   nuclear receptors 41  
   parathyroid hormone 198–9  
   thyroid hormone 89  
 respiratory alkalosis 211  
 retinoid X receptor 301, 302  
 retinopathy, diabetic 313, 317–21  
   glycated haemoglobin *vs* 245  
   *RET* proto-oncogene 57, 226, 232  
 retro-orbital pain 188–9  
 reverse T<sub>3</sub> and T<sub>4</sub> 169  
 reversibility of hormone–receptor interactions 30  
 rhythms 13  
   *see also* circadian rhythm  
 ribosomes 18  
 rickets 208–10  
 Riedel thyroiditis 175  
 rimonobant 349  
 RNA polymerase 17  
 rosiglitazone 303  
  
 salt wasting congenital adrenal hyperplasia 117–18

- sample collection 49b  
  hypercalcaemia 202  
  hypoglycaemia 217
- sandwich assays 50–1
- sarcoidosis, hypercalcaemia 200–1
- satiety centre 347
- saturability of hormone receptors 30
- schizophrenia, obesity 358–9
- scintigraphy *see* nuclear medicine
- screening  
  diabetes 294–5  
  depression 335  
  foot disease 327  
  nephropathy 321–2  
  retinopathy 318–20  
  MEN-1 224–6  
  MEN-2 226  
  *SDHB*, *SDHD* genes 227
- second messengers 30, 34, 37–40
- secretin **216**, 221
- secretory vesicles 20
- selective oestrogen receptor modulators 207
- selenodeiodinases 172  
  propranolol on 181
- self-antigens, diabetes 262
- semen analysis 134, 140
- seminiferous tubules 134, 135
- seminoma 141b
- sensory testing, diabetic neuropathy 327
- septo-optic dysplasia 90
- sequencing of genes 57
- serotonin **216**, 222
- Sertoli cells 134, 135  
  *see also* inhibin
- sex chromosomes 15
- sex determination, embryonic 128–30
- sex development, disorders of 130–4
- sex hormone-binding globulin 136, 139  
  polycystic ovarian syndrome 154  
  reference ranges **55**
- sex steroid precursors 107  
  tumours secreting 116
- sexual differentiation 129, 130, 131, 132
- sexual dysfunction, diabetes 313, 329–30, 341
- SH2 domains 31
- SH3 domains 31
- Sheehan syndrome 91
- short stature 82
- short Synacthen test 110
- sick euthyroid syndrome 174
- signal transduction 30–1  
  growth hormone 34, 35, 76  
  insulin 31–3, 34b, 248, 250, 291b  
  prolactin 34  
  second messengers 30, 34, 37–40
- sildenafil 330
- single nucleotide polymorphism arrays 57
- skin  
  cortisol action 105  
  pigmentation, adrenocortical insufficiency 88, 124
- sleep time, weight *vs* 353
- social aspects  
  diabetes 339–40  
  obesity 345
- sodium, homeostasis  
  aldosterone on 107  
  cortisol action 106  
  GH on 76
- sodium–glucose co-transporter 2  
  inhibitors 308
- soluble insulin 266–7
- somatostatin **215**, 219  
  analogues 80, **81**, 221  
  hypoglycaemia 218  
  reference ranges **55**
- somatostatinomas 219
- sorbitol 314, 315
- space-occupying lesions, pituitary tumours as 67–70, 96
- specimens *see* sample collection
- spermatogenesis 134
- spermatozoa, function 147
- spironolactone 116  
  for hirsutism 158
- SRY* gene, translocation 133
- stalk disconnection syndrome 85
- START domain containing 3 23
- STAT family proteins 34, 36
- static testing 52
- statins 23, 333
- steroid acute regulatory protein 23
- steroid hormones 9  
  nomenclature 23  
  receptors 41, 46  
  storage 23–4  
  synthesis 19, 23, 25, 103  
  enzymes **104**  
  fetus 150, 151  
  ovary 144  
  *see also specific hormones*
- steroidogenic factor-1 17, 42
- stimulus-response testing *see* dynamic testing
- stomach, hormone **10**
- stress 87–8  
  on gonadotrophin-releasing hormone 137  
  hypogonadism 90
- stroke, diabetes 330
- strontium ranelate 208
- sub-fertility 159–62, 164
- sulphonylureas 297–9, **307**  
  hypoglycaemia 217, 298  
  mechanism 246
- superfamilies, hormone receptors 29b
- suppression tests 52  
  dexamethasone 113, 114, 232
- surfactant (lung)  
  cortisol on development 106, 150–1
- Synacthen (tetracosactide) 110
- syndrome of inappropriate ADH 93, 97  
  Addison disease *vs* 109
- synthetic ACTH test 88, 110, 124
- syringes, insulin 270
- T<sub>3</sub> (tri-iodothyronine) 168, 169  
  metabolism 172–3  
  protein binding 172  
  reference ranges **55**  
  *see also* thyroid, hormones

- T<sub>3</sub>-toxicosis 184  
 T<sub>4</sub> (thyroxine) 168, 169  
   competitive-binding assay 51  
   metabolism 172–3  
   protein binding 172  
   reference ranges 55  
   replacement therapy 177, 187  
   antithyroid drugs with 180  
   *see also* thyroid, hormones  
 tadalafil 330  
 tamoxifen  
   breast cancer 229  
   endometrial cancer metastases 230  
 Tanner stages of puberty 138  
 target cell hormone conversion 41, 45  
 ‘TATA’ boxes 16  
 technetium isotope, pertechnetate 168  
 television, obesity and 352  
 teratogenesis  
   hyperglycaemia 336–7  
   *see also* congenital malformations  
 teriparatide 208  
 testis 134  
   embryology 128–30  
   hormone 11  
   tumours 141, 230  
   undescended 132  
 testosterone 135  
   diurnal variation 136  
   hirsutism 157  
   hypogonadism 139  
   negative feedback 137  
   polycystic ovarian syndrome 154  
   reference ranges 55  
   replacement therapy 140–1  
 testotoxicosis 39  
 tetrasactide 110  
 thelarche 151  
 thiazide diuretics, hypercalcaemia 200  
 thiazolidinediones 297, 299b, 301–3, 307  
 thirst regulation 71–2  
 thromboembolism  
   diabetic ketoacidosis 282  
   hyperosmolar hyperglycaemic state 293  
 thyroglobulin 168–71  
   iodination 170  
   reference ranges 55  
   resorption 171–2  
 thyroglossal cysts, positions 166  
 thyroid 165–89  
   anatomy 168  
   cancer 57, 185–6, 189  
   *see also* medullary thyroid carcinoma  
   dyshormonogenesis 175  
   function tests 174  
   amiodarone 184b  
   hypothyroidism 174, 177–8  
   hormones 10, 169  
   biosynthesis 168–72  
   function 173–4  
   growth hormone release 77  
   receptors 41, 46, 173–4  
   resistance 174  
   resistance syndrome 89  
   T<sub>4</sub> competitive binding assay 51  
   human chorionic gonadotrophin on 149  
   hypoplasia 167–8  
   radionuclide imaging 61  
   *see also* hypothyroidism  
   thyroidectomy 180  
   thyroiditis 175, 176, 189  
   thyroid peroxidase 170  
   thyroid-stimulating hormone (TSH) 88–9, 171, 174  
   hypothyroidism 177  
   reference ranges 55  
   synthesis 21  
   thyrotoxicosis 178, 179b, 188  
   thyroid nodules 185  
   thyrotrophin-releasing hormone 171  
   hyperprolactinaemia 97  
   thyroxine *see* T<sub>4</sub>  
   tolazide 298  
   tolbutamide 298  
   total contact casting 327  
   toxic adenoma of thyroid 184  
   *TPIT* mutations 91  
   transcription of genes 16–17  
   transcription factors 15, 16–17, 43, 47  
   translation of genes 18  
   transmembrane domains of  
     G-protein-coupled receptors 35, 38  
   transplantation, diabetic nephropathy 323  
   transport proteins 24  
   trans-sphenoidal surgery 80, 81, 114  
   triglycerides 252  
   tri-iodothyronine *see* T<sub>3</sub>  
   troglitazone 303  
   trophoblast 149  
   tryptophan deficiency 222  
 T-scores, bone mineral density 205–6, 207  
 TSH *see* thyroid-stimulating hormone  
 TSHomas 89  
 tumourigenesis 13  
 tumour suppressor genes 224b, 225  
 Turner syndrome 15, 133, 153, 159  
   management 153, 154  
 twenty-four-hour urine collections  
   calcium 201  
   5-hydroxyindoleacetic acid 222  
 two-hit hypothesis 224, 225  
 tyrosine, hormones from 22–3  
 tyrosine kinase receptors 30, 31–4  
  
 ultradian rhythm 13b  
 ultrasound 57–9  
   polycystic ovarian syndrome 154–6  
   pregnancy, diabetes 337  
   unawareness of hypoglycaemia 276, 277  
   driving and 339–40  
   United Kingdom, obesity 344, 346  
   United States of America, obesity 346–7  
 untranslated regions (UTRs) 17  
 uric acid, insulin resistance and 290b

- urinary catheters, diabetic
  - ketoacidosis 281
- urinary free cortisol 102
- urine collection
  - containers 49b
  - Cushing syndrome 113
  - see also* twenty-four-hour urine collections
- uterus
  - fibroids 158
  - menstrual cycle 145–7
  - oxytocin on 94–6
- vagina, menstrual cycle 145–7
- vaptans 93
- vardenafil 330
- variant nuclear receptors 41–2
- vascular endothelial growth factor (VEGF), diabetes 316
- vasoactive intestinal polypeptide (VIP) **215**, 220–1
  - reference ranges **55**
  - tumours secreting 219b, 221
- vasopressin 91–4
  - corticotrophin-releasing hormone and 87
  - molecule 8, 11
  - secretion 67
- venous sampling, parathyroid hormone 202
- Verner–Morrison syndrome 219b, 221
- vesicles, secretory 20
- VIPomas 219b, 221
- viral infections
  - thyroid 176
  - diabetes 262b
- virilization 116, 118, 119
- vision, diabetes 263, 340–1
  - see also* retinopathy
- visual field defects
  - pituitary tumours 67–8, 71, 96
- vitamin D 192–6
  - deficiency 208–10, 212
  - hypercalcaemia 200
  - inactivation 193
  - reference ranges **55**
  - see also* 1,25-dihydroxyvitamin D
- Von Hippel-Lindau syndrome **123**, 227
- waist measurement 346
  - diabetes risk 294b
- water
  - deprivation test **95**
  - homeostasis
    - aldosterone on 107
    - cortisol action 106
    - GH on 76
- weight gain
  - antidiabetes agents 298, 302–3
  - polycystic ovarian syndrome 157
- weight loss, diabetes 263
- weight management programmes 353–8
- weight regulation 347–53
- Wolffian ducts 130, 131
- World Health Organization
  - diabetes
    - classification 238–40, 241b
    - diagnostic criteria 240–1
    - obesity, definitions 344
- X chromosomes 15
- zinc fingers, steroid hormone receptors and 41
- Zollinger–Ellison syndrome 220
- zona fasciculata 102b
- zona glomerulosa 102b, 107
- zona reticularis 102b
  - tumours 116









